pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL
RIGEL PHARMACEUTICALS
RIGEL PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS clinical programs — 26 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1180 Veterans Blvd, South San Francisco, CA 94080, US
- Founded
- 1996
- Employees
- 286
- Programs
- 36
- Drugs
- 26
- Patents
- 373
RIGEL PHARMACEUTICALS projects
26 ClinicalTrials.gov programs sponsored by RIGEL PHARMACEUTICALS.
RIGEL PHARMACEUTICALS has 26 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Fostamatinib
RIGEL PHARMACEUTICALS INC
Hidradenitis Suppurativa
1 trial -
Fostamatinib
RIGEL PHARMACEUTICALS INC
Myelofibrosis
1 trial -
Fostamatinib 150 mg
RIGEL PHARMACEUTICALS INC
IGA Nephropathy
1 trial -
Fostamatinib 150 mg bid
RIGEL PHARMACEUTICALS INC
Warm Antibody Autoimmune Hemolytic Anemia
1 trial -
Fostamatinib Disodium
RIGEL PHARMACEUTICALS INC
T Cell Lymphoma
1 trial -
Fostamatinib Disodium (R935788)
RIGEL PHARMACEUTICALS INC
Systemic Lupus Erythematosus
1 trial -
Fostamatinib Disodium / R935788
RIGEL PHARMACEUTICALS INC
Purpura, Thrombocytopenic, Idiopathic
1 trial -
Fostamatinib Disodium tablet 100 mg
RIGEL PHARMACEUTICALS INC
IGA Nephropathy
1 trial -
Fostamatinib disodium (R935788)
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
2 trials -
LY3871801
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Myelodysplastic Syndromes
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Targeted Therapy
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Acute Myeloid Leukemia
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Chronic Myelomonocytic Leukemia
1 trial -
Olutasidenib
RIGEL PHARMACEUTICALS INC
Mutant IDH1 Inhibitor Olutasidenib
1 trial -
Olutasidenib + TMZ
RIGEL PHARMACEUTICALS INC
High Grade Glioma
1 trial -
Placebo
RIGEL PHARMACEUTICALS INC
Asthma
1 trial -
Placebo
RIGEL PHARMACEUTICALS INC
Acute Respiratory Distress Syndrome
1 trial -
R348 Ophthalmic Solution, 0.2%
RIGEL PHARMACEUTICALS INC
Keratoconjunctivitis Sicca
2 trials -
R348 Ophthalmic Solution, 0.2%
RIGEL PHARMACEUTICALS INC
Chronic Graft-versus-host Disease
1 trial -
R788
RIGEL PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
R906289 Monosodium (R289 Na)
RIGEL PHARMACEUTICALS INC
Low Risk Myelodysplastic Syndromes
1 trial -
R926112
RIGEL PHARMACEUTICALS INC
Rhinitis, Allergic, Seasonal
1 trial -
R932333
RIGEL PHARMACEUTICALS INC
Lupus Erythematosus, Discoid
1 trial -
Ruxolitinib
RIGEL PHARMACEUTICALS INC
Coronavirus
1 trial -
fostamatinib
RIGEL PHARMACEUTICALS INC
Lymphoma
1 trial
Frequently asked questions
How many clinical projects does RIGEL PHARMACEUTICALS have?
26 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.